drugset / Trial / NCT07557004
A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.
NaSequentialOpen-labelTreatment
Summary
Evaluate the efficacy and safety of the SH3765 tablet combined with fulvestrant in the treatment of patients with advanced HR-positive breast cancer
Timeline
- Start
- 2025-09-30
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SH3765 | Unknown | 40 mg | Oral |
| Subject | SH3765 | Unknown | 60 mg | Oral |
| Background | Fulvestrant | Small molecule | 500 mg | Intramuscular |